Hanmi Pharmaceutical 1 trillion9,000 hundred million won in technology exports; robotics stocks also surge
Hanmi Pharmaceutical has agreed to transfer technology for a new drug for digestive diseases to Lilly for 1 trillion9,000 hundred million won. The upfront payment was 1,100 hundred million won, and the stock's rise of 13% was confirmed; robotics stocks also surged after Jensen Huang was mentioned.
Get free 한미약품 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Hanmi Pharmaceutical has agreed to transfer technology for a new drug for digestive diseases to U.S. pharmaceutical company Lilly for 1 trillion9,000 hundred million won. The company disclosed that the agreement includes rights to indications and development conditions tied to milestones. The signing of the agreement was immediately reflected in a market disclosure.
The upfront payment was reported to be 1,100 hundred million won. Hanmi Pharmaceutical shares rose 13% that day. The company said it would disclose the milestone and royalty structure separately at a later date.
Related stocks surged after Jensen Huang singled out LG Group stocks in his remarks. Some LG affiliates rose more than 10% in premarket trading. Doosan Robotics closed at the upper price limit.
In the market, expectations for ‘Je2’s ‘Kkanbu meeting’ spread, lifting robot-related stocks across the board. Trading in small- and mid-sized robot stocks rose sharply during the session. Some investors bought shares citing the possibility of a partnership with Nvidia.
Ultimately, Hanmi Pharmaceutical’s large-scale technology export and remarks by key figures both drove share-price movements in that day’s session. The original disclosures and detailed contract terms of each company were reflected in the day’s market prices. Investors checked the disclosure details themselves.